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Obj,,ti,,s. We examined the results of coronary artery bypass 
graft surgery after thromboiytic therapy in the Thromboiysis in 
Myocardiai Infarction trial, Phase II (TIM1 XI) with particular 
emphasis on patient characteristics, the impact of antecedent 
percutaneous transluminai coronary angioplasty and morbidity 
and mortality in certain subgroups. 
Backgtound. Coronary bypass surgery is frequently used after 
thromboiytic therapy, but there is relatively little information with 
regard to early and late outcomes. 
M&n&. We analyzed 3,339 patients enrolled in the TIM1 II 
trial. Bypass suqery was performed in 390 patients (11.7%): 54 
(14%) within 24 h after entry into the trial or within 24 h of 
coronary angiopiasty and 336 (86%) between 24 h and 42 days 
after entry. 
Results. Perioperative mortality rates were, respectively, 16.7% 
and 3.9% (p < 0.001); perioperative myocardiai infarction rates 
were 5.6% and 6.20/o, respectively; and major hemorrhagic events 
occurred in 74% and 50.%, respectively (p = 0.002). On mu&i- 
The benefits of thrombolytic therapy iF decreasing early mor- 
tality after acute myocardial infarction have bzcn demon- 
strated unequivocally in several large randomized trials (l-5). 
It has also become clear that late mortality is surprisingly low 
(6,7), particularly compared with published series antedating 
the use of thrombolytic therapy (8); but a single unified 
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variate analysis, the only independent predictor of perioperative 
mortal was bypass surgery within 24 h after entry or after 
coronary angiopiasty. Among patients undergoing bypass surgery 
within 24 h of entry or after coronary angiopiasty, the prevalence 
of multivessel disease (59.1% vs. 77.8%) and use of the internal 
thoracic artery (18.5% vs. 62.5%) were lower than in the remaining 
surgical patients. Among the 322 perioperative survivors, the 
l-year mortality rate after discharge was only 2.2% and 1.9%, 
respectively, in the two groups. Only one patient had a doeu- 
mented recurrent myocardiai infarction during the first year. 
Conclusions. The increased mortality rate with bypass surgery 
after thromboiytic therapy, particularly in patients undergoing 
operation within 24 h of coronary angiopiasty or during the 
invoiviq phase of infarction, must be balanced against tbe 
excellent I-year prognosis and perioperative survivors, who are in 
general a group at higher risk of death or recurrent infarction. 
These data provide a basis for comparisca for future studies. 
(J Am Coil Car&l 1995;25:395- 402) 
hypothesis does not explain the strikingly low late mortality. 
Mechdnisms complementing myocardial salvage have been 
proposed, including the poteniial for a patent infarct-related 
artery to have a beneficial effect on ventricu!;r remodeling or 
electrical stability and to act as a source of future collateral 
vessels (6,7,Y). Stringent selection criteria for thromboly?ic 
therapy may be related to outcome (lo), but the frequent use 
of coronary revascularization after thrombolytic therapy has 
been suggested as an additional factor contributing to the low 
late mortality and cardiac morbidity. 
In the Thrombolysis in Myocardial Infarction trial, Phase II 
(TIM1 II), the administration of the lytic agent was only one 
aspect, albeit a crucial one, of an overall therapeutic approach 
that included coronae revascularization by coronary artery 
bypass graft surgery or percutaneous transluminal coronary 
angioplasty (11-13) for appropriate clinica indications. The 
role of coronary angioplasty has been addressed in several 
randomized and nonrandomized studies (1 l-15), but there is 
relatively little information on the Parly and Iate outcomes of 
bypass surgery after thromboiytic therapq other tharl reports 
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documenting the feasibility of the technique during the early 
postlysis period (1.6-21). Therefore, we examined the results of 
bypass surgery after thrombolytic therapy in the TIMI II trial, 
with particular emphasis on the characterislics of the patients 
selected for coronary bypass, the impact of antecedent coro- 
nary angioplasty and morbidity and mortality in speciiic sub- 
groups of patierris. 
Methods 
Trial design. The TIMI II trial was designed to evaluate 
the role and timing of angiography and coronary angioplasty in 
patients treated intravenously with recombinant tissue-type 
plasminogen activator (rt-PA) within 4 h after an acute myo- 
cardial infarction characterized by ST segment elevation at 
presentation. The primary comparison of management strate- 
gies was based on the occurrence of death or myocardial 
infarction within 42 days of study entry. D&Is of the trial 
desig,n have been published (Il-13), including a substudy 
(TIMI IIA) of patients who underwent angiography and 
coronary angioplasty (when the coronary anatomy was suit- 
able) immediately. In the TlMl IIB s&study, patients eligible 
for beta-adrenergic blocking ngent therapy were randomly 
assigned to immediate intravenous administration of metopro- 
lol (started during the rt-PA infusion) followed by oral treat- 
ment or deferred oral therapy with metoprolol starting 6 days 
after i-t-PA infusion (22). 
Patient population. Between April 11, .986 and June 30, 
1988,3,339 patients were entered in the TIM1 II t.rial. Of these, 
390 underwent coronary bypass within 42 days rfenrollment in 
TIM1 i1. The population: undergoing coronary bypass evalu- 
ated ir: the present analysis irlciudes patients in TIM1 II 
assigned to either protocol-directed catheterization (206 pa- 
tients) 18 to 48 h after study entry (invasive strategy) or the 
conservative strategy of catheterization only when clinically 
indicated (183 patients). 
The details d the administration of rt-P.4, heparin and 
aspirin; methods of treatment assignment; and managemec: 
strategies have :+-en :‘:scribed elsewhere (ll-13,22). Risk of 
unfavorable outcome was assessed on the basis of age, previous 
myocardial infarction, anterior myocsrdial infarction, rates, 
hypctension and tnchycardia, atrial fibrillation or Ilutter, pul. 
monary edema and cardiogenic shock (11,12,231. 
B;pass surgery was recommended in the ‘1‘IMI II protocol 
for invasive strategy group patients with a lumen obstruction 
270% in the left main coronary artery (n = IO) or with 
coronary anatomy that provided technical obstacles co coro- 
naly angioplasty (e.g., distal lesions in a tortuous vessel) in 
whom bypass surgery was the treatment of choice (n 87). In 
the ml?jority of patients in tile conservative strategy group, the 
indications for bypass surgery were brsed on a combination 
of anatomic findings and clinical observations (e.g., rest or 
exercise-induced ischemia in patients with ~70% lumen ob- 
struction in more than one major artcry that was perfusing 
normally, contracting or hypokinetic myocardium and coro- 
nary arteries anatomically unsuitable for coronary angio- 
plasiy), 
The techniques of anesthesia, coronary @$ass and postop- 
erative management were those in use at the individual 
institutions participating in the study. 
Predismissal and follow-up studies. The techniques for 
measuring rest left ventricular function aiid for exercise radio- 
nuclide ventriculography have been described elacwhere (1 I- 
13,24). Coronary angiography was performed using standard- 
ized projections. Contrast left ventriculography was performed 
in the 30” to 35” right anterior oblique projection. 
Statistical analysis. Proportions were compared by using 
standard Z tests (25). Mean values of continuous variables 
were analyzed by using the Student t test for two-group 
comparisons. To adjust for multiple testing, two-sided p values 
between 0.01 and 0.001 were specified as providing some 
evidence of differences and p < 0.00: as providing strong 
evidence of differences. Data analyses were performed using 
the SAS statistical software package (26) and a data file 
established in January 1991. Survival curves were calculated 
using the methods of Kaplan and Meier (27), and comparisons 
of these rates were tested using the log rank statistic. Periop- 
erative mortality is presented as the percent of patients who 
died before hospital discharge or within 30 days of bypass 
surgery. 
Comparisons of event rates adjusted for patient character- 
istics were made with the Cox proportional hazards model (28) 
lis;n,: BioMedical Data Pack Age (BMDP) program? (29). 
Faults 
Patient groups. The 3VO patients who underwent bypass 
srrgery were classified into two groups according to when the 
operation was perfnrmed: 54 patients who underwent bypass 
surgery within 24 h after entry into the irial or within 24 h of 
coronary angioplasty performed within 42 days of enrollment 
in TIM1 II (group A) and 330 patients who underwent bypass 
surgery between 24 h and 42 days after entry (group B) (Table 
1). Perioperative mortality and morbidity were similar between 
patients operated on between 24 h and 7 days and between 
days 8 and 42. Therefore, tt,PSe patients were combined into a 
single group foitl subsequent analyses. 
Baseline characteristics. Clinical vutiuabies. Patients un- 
dergoing “en?Prgcncy” or “urgent” operation (group A) were 
younger than thhjse undergoing bypass surgery >24 h after 
study entry or coronary angioplasty (Table 1). The majority of 
patients in botn groups (63% and 74%) undergoing bypass 
surgery were considered nnt to be at “low risk” of an adverse 
0u:comc. 
Cmdiac catkwization variables. PrecTerative coronary an- 
giography was performed in all 390 patients undergoing bypass 
surgery (206 of whom were assigned to the invasive strategy) 
(Table 2). The infarct-related artery was the right coronary 
artery in 42%, the left anterior descenndng coronary artery in 
-41% and the circumflex coronary artery in 13%. The infarct- 
related arteries were similar in the tNo groups (p = 0.83). In 
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Table I. Baseline Characteristics, by Timing of Bypass Surgery* 
.- IIIcI.---I-~ --. I - 
Group A: Group B: 
Overall CABG ~24 h CARG 24 h to 42 days 
(n = 3%) (II = 54) (II = 336) 
-__ 
No. No. No. 
of Pts %I or Pts % of Pts 76 
- 
Mean (+SD, (yr) rge 59.7 + 9.5 55 + 10.8 60.4 2 9.0t 
Male gender 330 54.6 42 77.8 288 85.7 
White race 355 91.0 48 88.9 307 91.4 
Not low risk 283 72.6 34 63.0 249 74.1$ 
Age ~70 yr 63 16.2 6 11.1 57 17.0 
Prior MI 96 24.6 11 20.4 85 25.3 
Anterior MI 197 50.5 27 50.0 170 50.6 
Rales 2% lung field 22 5.6 3 5.6 19 5.6 
Hypotension and sinus tachycardia 26 6.7 6 11.1 50 6.0 
Atrial fibrillation or flutter I5 3.8 0 0.0 15 4.5 
Pulmonary edema 8 2.1 0 0.0 8 2.4 
Cardiogenic shock 9 L.3 3 5.6 6 1 .X$ 
Other risk factors 
Previous angina 275 70.5 3i; 70.4 237 70.5 
Congeslive hcarl fiiilUK 15 .I.t( 1 1.8 14 4.2 
Hypertension 172 44. I 22 40.7 150 44.6 
Diabetes mellitus 5x 14.9 4 7.4 54 16.1 
Ongoing chest pain at rt.PA 347 89.0 46 85.2 301 X9.6 
initiation 
Treated ~2 h 115 29.5 14 25.9 101 30.0 
Mean (.?SD) time from onset of 2.57 + 0.92 2.53 t 0.84 2.57 it 0.93 
pain to study entry (h) 
---l__ll_ 
*Of the 54 patients (Pts) operated on within 24 h, 22 underwent coronary artery bypass gra:i surgeiy (CABG) within 
L4 h of study entry and 32 within 24 !L cf attc m$xJ ;xxtneous !ransluminal coronary angioplasty (PTCA). “rp < 0.001 
between groups A and B. fp = 0.09 between groups A and B. MI = myocardial infarction; r;-PA = recombinant 
tissue-type plasminogen activator. 
310 patients, the number of vessels diseased was documented; 
mu!tivessel disease was present in 75% and triple-vessel dis- 
ease in 28% (Table 2). The Ltistribution of coronary artc;jr 
d&se amop; patients undergoing bypass surgery in 5iO-F .% 
was different from that among those Gpraied on L+ter (group 
13) (p = 0.018). Single-vessel dust dse was present in 41% of the 
44 patients in the former grout, in whom the: coronary ar atomy 
was reviewed hy TIMI II irr.;. Ltgators for the: study but in only 
?ZL of patients undergoing bypass surgery after 24 h (p = 
NOS). Tine distribution and extent of coronary disease differed 
strikingly between the patienis in the invasive group undergo- 
ing bypass rurgery and the 1,475 patients assigned to the 
invasive stratcgJr who did not undergo operation. Or the 1,347 
patients in the latter group in whom the number of vessels with 
&O% stenosis was known, only 27% had multivessel disease, 
and 5% had tr$)le-vessel disease (30). 
Clinical status before bypass surgery. Sixty-three percent of 
patients undergoing bypass surgery had definite or probable 
i:ikgina, and of these, 79% were in Cszldian Cardiovascular 
Society class Iii or KV. This included patients assigned to the 
invasive strates who underwent protocol-directed catheteriza- 
tion and subseque;it bypass surgery. 
In group A F. ::ents (those undergoing bypass surgery 
within 24 h of study entry or wirXn 24 h of an attempted 
coronary angioplasty), only 1 (1.8%) of 54 operations was 
categorized as elective, whereas it was categorized as elective 
in 66.7% of patients operated on between 24 h and 4: days of 
study entry. The indications for bypass surgery are presented in 
Tab!e 3. 
The use of intrarlortic balloon counterpulsation in TIMI II 
was documented for patients undergoing bypass surgcly during 
the initial TIMI II hospital period. In group A, 58.5% of 
patients were treated with intraaoriic balloon counterpulsation 
preoperativeiy, including 13 of the 14 patients reported to be in 
shock. In the 24-h to 42-day bypass surgery group, 20% of 
patients in total were treated with intraaortic balloon counter- 
pulsation during their initial hospital stay. 
Preoperutivc left ventricihr finnctiotl. Prcaperative ejection 
fraction determined by contrast ventricufography was avai@le 
for 43% of patients with bpass surgery and was >0.5Q in 3S%, 
0.35 to 0.50 in 46% and co.35 m 19%. Mean ejection fraction 
was 045 ?Z 0.13 and 0.46 -C 0.12 in groups A and B, 
respectively. Preoperative ejection fraction from rest radionu- 
ciide ventriculography was availablr for 67% of patients and 
was >0.50 in 55%, 0.35 to 0.50 in 32% and co.35 in l~!‘/c~. 
Xean ejection fraction with this technique was 0.52 zz 0.15 and 
0.51 f 0.14 in groups A and B, respectively. When the highest 
value obtained by either :cchnique was used, 48% of patients 
had an ejection fraction <0.50; but no measurement of ..‘jec- 
tion fraction was obtained irl 69 of the 390 patients. 
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Table 2. Byyxs Surgery in Thrombolysis in Myocardial Infarction Trial, Phase II: Cardiac 
Cathetcriz&n Before Operation 
Group B: 
Group A: CABG 24 h to 
0vcrall CABG ~24 h 42 days 
(n = 3%)) (n = 54) (n = 336) 
No. NO. No. 
or Pis ‘i;, of P!S q; of Pts q, 
11~-~- 
No. of pts with o11c catheterization before CABG 51 318 
Infarct-related artery* 
RCA 1.55 420 23 45.1 132 41.5 
L!1CA 4 1.1 1 2.0 3 0.9 
LAD 151 40.9 22 43.1 129 40.6 
CX 48 lj.0 4 7.8 44 13.8 
None 1 0.1 0 0.0 1 0.3 
Not identified 10 2.7 1 2.0 9 2.x 
No. crf vesscis with zhO’% stenosis’ 
0 5 1.4 0 0.0 5 1.6 
1 72 19.5 IX 35.3 54 17.0 
2 ! ‘7 39.8 20 39.2 127 39.9 
3 Xh 23.3 6 11.8 80 25.2 
Not identified 59 IS.9 7 13.7 52 16.3 
~- - - 
*Assessed on first cardiac catheterization only. Cx = circumflex coronary artery; LAD = left anterior descending 
coronary arery; LMO = left main coronary artcry; RCA = right coronary artery; other abbreviations as in Table 1. 
Coror~ary artery bypass surgery. Mop-wfive morbidity 
rind monuli6y. Overall, 95% o f patients received saphenous 
vein grafts and 62% had internal thoracic artery conduits. Of 
the 369 patients undergoing bypass of the left antcricir de- 
scending coronary artery system, 59% had internal thoracic 
artery conduits Amnr g patients undergoing bypass within 24 h 
after coromuy angiopkty after entry into the study, the 
internal :horawc a:tery was used in only 18.5% compared with 
62.5% of patients undergoing bypass between 24 h and 42 days. 
Periopcrathe mortality (defined as death within 30 days or 
before dismissal from the hospital) was 5.6% overall; it was 
16.7% and 3.YCX (p < 0.001) in groups A and 8, respectively 
(Fig. 1A). In the 32 patients undergoing operation within 24 h 
of coronary angioplasty, the perioperative mortality rate was 
15.6%. Perioperative myocardial infarction was documented in 
5.6% and 6.2% (p = U.96) of patients in groups A and B, 
‘hblc 3. Indicatiot,s for Bypass Surgery 
respectively (Table 4, Fig. 1B). Perioperative mortality rate is 
presented in Table 5, according to the timing of bypass surgery 
and tke reason for bypass surgery (distinguishing six categories 
of Jinical conditions associated with emergency operation). 
Bypass surgery within 24 h of a complicated coronary angio- 
plasty is associated Gth high perioperative mortality rate. 
Preoperative ejection fraction was cot reported in 26 (48%) of 
the 54 patients undergoing operation within 24 h (group A) 
and in 92 (27%) of the 336 patients undergoing operation 
within 24 h to 42 days (group 8) (p = 0.002), suggesting a 
degree of ascertainment bias. Among grnup A patients in 
whom ejection fraction was ascertained, mortality was 29% in 
thobe with an ejection fraction CO.50 as opposed to Co/o in 11 
patients with an ejection fraction >0.50. Among group B 
patients with an ejection fraction ~0.50, perioperative mortal- 
ity rate was 61;; as opposed to 2.7% in those with an ejection 
Group A: CABG Group B: CABG 
Overall ~24 h ‘?4 h IO 42 days 
(n ; 300) (II = 54) (n =: 336) 
I- _, _-.-- _...---- ~--- 
No. NO. No. 
:d pi, (7 of Ph % of 3s % 
--~-~ - .---- -__I___------ -_____ 
Elective ‘25 51.5 I 1.8 224 66.7 
Emergency (clinical condition) 
Angina without definite ECG changes 36 9.2 3 5.6 33 9.R 
Angina with ECG changes 40 10.3 5 9.3 35 10.4 
Persistent cheit pain and ST elevation ‘?I 5 4 I? 22.2 Y 2.1 
Oiher (Is&d;:; c(ilflfl!k::!:c1*5 koni FfU) h8 174 33 61.1 35 10.4 
--...--..-I~-___- ._ ---l--l_______ 
KG = ztectrocardiographic; othc, dbbrcviations as in Table 1. 
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Figre 1. Cumulative Kaplan-Meier mortality curves (A) and cumu- 
lative recurrence of infarction (B) from date of coronary artery bypass 
graft surgery (CABG) to 30 days. Solid line = patients undergoing 
operatiorr within 24 h of entry into the study or after coronary 
angioplasty; dashed line = patients undergoing operation between 
24 h after entry and 42 days. 
fraction Hl.50. In patients with an ejection fraction ~0.35, 
perioperative mortality rate was 50% and 10.8% in groups A 
and B, respectively. 
Major surgical hemorrhagic events (defined as a blood loss 
of ~5 g/dl) occurr:d in 40 patients (74.1%) operated on within 
24 h of study entry or coronary angioplasty and in 171 patients 
(50.9%) undergoing bypass surge9 within 24 h to 42 days of 
study entry (p = 0.002) (31). Mean (tSD) units transfused 
were 4.8 rt 4.4 U for the 53 patients in group A and 3.5 r 3.0 U 
for 270 patients in group B (p = 0.006) undergoing bypass 
surgery during the initial TIMI II hospital period. 
Late events. Among the 322 perioperative survivors, there 
were only 7 late deaths during the first year, giving rise to 
l-year mortality rate after discharge of 2.2% and 1.9% (p = 
0.88) in groups A and B, respectively. Only one patient had a 
documented nonfatal recurrent myocardial infarction during 
the first year. Complete follow-up data are available for TIM1 
II patients only through 2 years. In the interval from the end of 
the first year of follow-up to the beginning of the second year 
of follow-up, no patients in group A died, and only six patients 
in group B died. 
Adjusted analyses. From the Cox proportional hazards 
regression models, the only independent predictor of periop- 
erative mortality was the performance of surgery within 24 h 
after entry into the trial or within 24 h of coronary angioplasty. 
Other variables examined (none of which was significant) were 
gender; race; age; anterior infarction; history of previous 
myocardial infarction, congestive heart failure, hypertension, 
previous angina or diabetes; and the timing of thrombolytic 
therapy. No analyses of late events were performed because 
there were too few late deaths or recurrent infarctions for 
adjusted analyses. 
Discussiom 
Frequency of bypass surgery after thrombolytic therapy. A 
recent meta-analyss (32) suggesitx! thdt for pattcins of g,zc. 
tice in North America, intravenous thrombolytic therap!- for 
evolving myocardial infarction is associated with a signikant 
(,-go%) short-term increase in subsequent coronary revasctl- 
larization procedures compared with patients receiving con- 
Table 4. Bypass Surgery in the Thrombolysis in Myocardial Infarction Trial, Phase 11: 
Events After Operalion _____---. 
Group A: CABG Group B: CABS 
Overall <24 h 24 h to 42 days 
No. of No. of No. of 
Pts 72 PtS % PtS Oh 
I___- ____II- 
Perioperative events* 
Death 2213313 5.6 9154 '67 131336 3.9 
MI 241396 6.2 354 5.6 Xi336 6.2 
Death or MI 37/390 9.5 9154 ’ 6.7 2Ri.336 x.3 
Events after the perioperative period 
thmugh 1 year from CAB@ 
Death 71366 1.9 :,'45 2.2 61321 1.9 
MI 11366 0.3 I?45 0 0 11321 0.3 
Death or MI 71366 1.9 1145 2.2 61321 1.9 
--- 
*Events through 311 days or hospital discharge for patients in the hospital >30 days. iEvents in 1 tear after 30 days 
from coronary artery bypass graft surgery (CABG) or hospital discharge ful patients in the hospital >30 days. Other 
abbrevikons as in Tsbl- 1. 
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Table 5. Perioperative Mortality According to Time of Bypass Surgery and Reason for Operation 
Group R: CABG 
Group A: CABG <?4 11 24 h IO 42 days 
- -~-- 
Pcriopcr.itivc Periopcr:lbve 
Oeathu 
No, -___A 
Dc;.ths 
No. --- 
Kcwn for Ojxrat ion of PIS No. 9 of Pts No. “r 
-_---~ ---i_ I__-~ 
Elrctive I I) Ml 224 5 2.2 
Energenq (clinical contlition) 
Angina without definite ECG changes 3 0 0.0 33 3 9.1 
Angina with ECG changes 5 (I 0.0 35 I 2.8 
Persistent chest pain and ST segment 12 3 25.0 9 0 0.0 
elevation 
Complication of protocol PICA 18 2 11.1 0 0 - 
Complication of nonprotocol PTCA 10 3 30.0 2 0 0.0 
Other 5 I 20.0 ?I? 4 12.1 
-___-----l_l-l- - _- 
Abbreviations a5 in Tables I and 3. 
ventional therapy. The frequency of bypass surgery during ihe 
initial hospital stay of patients undergoing :hrombolytic ther 
spy for acute myocardial infarction was -38% in six series 
totaling 2,076 patients (33). In the Interuniversity Cardiology 
Institute of The Netherlands Trial, during the first 3 years after 
dismissal, either bypass surgery or coronary angioplasty was 
performed in 35% of patients treated with thrombolysis and in 
27% of patients treated conventionally (34); 17% of the 
patients in the TIMI I trial underwent bypass surgery during 
the first year (compared with 16% in this TIM1 II trial), and 
either bypacs surgery or coronary angioplasty had been per- 
formed in -44% at 12 months (35). 
These data emphasize Lurrcnt p;ac!ice trends toward tL I 
more frequent use of bypass sur;ery as one aspect of a 
comprehensive therapeutic strafcg: of acute myocardial infarc- 
tion, with thlombolytic therapy as Ihe first step 
Characteristics of patients unoerguing hypas- surgeq. Of 
the 54 patients undergoing operation withm 74 h of entry into 
the study or after coronary angio$rrty, only 1 patient was 
categorized as h:Gng an CLXI tie operation. The remainder 
had either persistent Anna UP PUP &c:i!ic)Tcs after angioplasty. 
In contrast, in phiiem: ,v, lrpi.;in!: peration within 24 h to 42 
days from ent?. --69; vi ,ile pioccdures were categor:s.ed as 
elective. 
As in most surgical series, the majority of pa:icnts had 
severe angina and multiv:sscl d&case. In patients randomized 
to the invasive arm, the operation was carried out in accord 
with the protocol because of crltical coronary obstruction that 
was not suitable for coronary angioplasty. Among patienis in 
whom ejection fraction d:Ja were available, left ventricular 
dysfunction (ejection fra&~l ~0.51)) was present in 65% and 
45% of patients by use of contrast ventriculography artd 
radionuclide anglography, respectively. 
Specific indications for bypass s’1rgery were not systemati- 
cally collected in TIM1 II, particularly because 67 of $U 
patients undergoing bypass surgery underwent operation after 
the initial hospital pc~iod. The dais arc therefore confined to 
patients undergoing operation within the initial hospital pe- 
riod. As illustrated in Table 5, among group A patients 
undergoing bypass surgery, this was due to complications of 
coronary angioplasty in 30 patients and persistent chest pain 
with ST segment elevation in 12 patients. Among group B 
patients undergoing operation within 24 h to 42 days, the 
majsrity of operations were considered elective, but specific 
details are unavailable. 
Distribution of coronary artery disease. In TIMI II, as in 
many other trials of thrombolytic therapy, only patients with 
ST segment elevation were eligible for inclusion (12,14). In 
most studies (including TIM1 II), patients with ST segment 
depression as their o&y presenting electrocardiographic ab- 
normality, a subgroup with a high incidence of multivessel 
disease (36,37), were excluded. Consequently, in this study, as 
in other trials of thrombolytic therapy, the prevalence of 
multivessel and particularly triple-vessel disease is low (7,ll). 
The more frequent and :lppropriate use of coronary artery 
bypass surgery in patients with more extensive disease is 
illustrated by the higher prevalence of multivessel (75%) and 
triple-vessel (28%) disease in surgically treated patients. 
Perioperative morbidity and mortality. In TIM1 II, the 
higher earlier mortality in patients undergoing bypass surgery 
within 24 h after study entry or after coronary angioplasty is 
consistent with other report:5 (38,35) of mortality after emer- 
gericy procedures and with the greater prevalence of hypoten- 
s;on and cardiogenic shock among these patients. That coro- 
nary bq’pzss Furgery within 24 h of a complicated coronary 
angioplasty is associalcd with a high mortality is not surprising 
and I!: consistent with other reports. In a recent analysis of the 
1989 experience with coronary angioplasty in the state of 
California, the mortality rate was 12.0% for patients with acute 
myocardia! infarction who underwent bypass surgery after 
coronary angioplasty and 5.6% (p = O.WOl b among patients 
with ;I\macute infarction who underwent operation after cor- 
onarl; angiopiasty (40). Klclman et al. (41) evaluated the 
mechanisms Jf early death in patients in the TIM1 II trial. 
Among the ;i3 patients who died within 18 h of stu..iy entry, 
pump failure wa: the attributed mechanism in 62%. The 
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urgency of the surgical procedures could explain the low 
utilization of the internal thoracic artery as a conduit in this 
group of patients (20% as opposed to 69% among patients 
undergoing operation after 24 h). 
Acute coronary syndromes increase the risk of coronary 
angioplasty, probably hecause of residual mural thrombus 
associated with plaque rupture ,11,14,42). The majority of 
operations performed within 24 h after coronary angioplasty 
were related to a complication or an unfavorable result of the 
procedure. Analysis (43) of complications in the National 
Heart, Lung, and Blood Institute PTCA Registry from 1985 
and 1986 showed that the mortality rate for emergencv by-pass 
surgery was 7.9%, which is substantially less than the 15.2% 
among patients in this study undergoing operation within 24 h 
after coronary angioplasty. Comparisons of different series 
have limitations; nonetheless, these data ell,phasize the risk of 
bypass surgery for failed coronary angioplasty in postinfarction 
patients, some of whom will have significant left ventricular 
dysfunction and multivessel disease. 
The TIMI II investigators previously reported (42) that 
there was an increase in the occurrence of hemorrhagic events 
associated with invasive procedures after thrombolytic ther.+y. 
In the present study, there is no specific data suggesting that 
thrombolytic therapy was responsible for any differences in the 
occurrence of hemorrhagic events, but it is likely that among 
patients undergoing bypass surgery within 24 h of study entry, 
thrombolytic therapy could have contributed to the occurrence 
of perioperative hemorrhagic events. Nonetheless, the high 
morbidity and mortality among patients in this group is most 
likely the consequence of :I greater severity of their initial 
illness, requiring emergency bypass surgery. 
Among patients undergoing bypass surgery later (between 
24 h and 42 days after entry), the perioperative mortality (ate 
of 3.9% is still higher than that found in other series of isolated 
bypass surgery in patients with chronic stable angina (44,45). 
The explanatisn mcjsl likely is multifactorial and related in :t:*rt 
to left ventricular dysfunction in patients with recent myocar- 
dial infarctior\ and mnltivessel disease (37,46,47). Moreover, 
the adverse e&t of left ventricular dysfunction on operative 
mortality during the early postinfarction period was empha- 
sized by Hochberg et a!. (48). Perioperative morta;;sy rates in 
patients who had an ejection fraction <OS0 were 19%, 18% 
and 11% in those undergoing bypass rdrgery within 3,4 and 5 
weeks after infarction, respectively, ar?d 6% in those undergo- 
ing bypass surgery >5 weeks after infarction, 
Bypass surgery and late mortality. It would appear that the 
TIM1 surgical population was, in the main, a group with severe 
coronary disease on the basis of the prevalence of left ventric- 
ular dysfunction, multivessel disease, severe angina occurring 
early after infarction and failure of or unsuitability for coro- 
nary anginplasty. Moreover, 24.6% of the patients in the study 
had a history of myocardial infarction antedating the TIMI 
infarction, which is considerably higher than the 14% docu- 
mented among the 3,339 patients in the overall TIMI II trial 
(49). A history of previous myocardial infarction is an impor- 
tant predictor of an adverse prognosis after thrombolytic 
therapy (50). It is thus encouraging to note the very low 
incidence of late events-only six deaths and one recurrent 
myocardial infarction at 1 year in perioperative survivors. This 
is similar to that reported for the overall TIMI II trial of 3,339 
patients (49), in which mortality from 6 weeks to 1 year was 
2.2% and the rate of reinfarction was 2.6%. 
Conclusions. The TIM1 II study provides detailed data for 
>390 patients undergoing bypass silrgery within 6 weeks of 
thrombolytic therapy. The high mortaliQ.in patients undergo- 
ing operation within 24 h of coronary angloplasty or during the 
evolving phase of infarction is emphasized. In patients under- 
going bypass surgery between 24 h and 42 days after entry, the 
mortality rate of 3.2% is increased compared with that in other 
series of patients with chronic stable angina, but this must be 
balanced against the excellent l-year prognosis in periopera- 
tive sutivors, who were, in general, a group at high risk ol 
death or recurrent infarction. These observations cannot nec- 
essarily be extended to all patients undergoing bypass surgery 
after myocardial infarction (with or without thrombolytic 
therapy), but the data provide a basis for comparison with 
future studies. 
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